166 related articles for article (PubMed ID: 26524088)
21. Peptide-Driven Targeted Drug-Delivery System Comprising Turn-On Near-Infrared Fluorescent Xanthene-Cyanine Reporter for Real-Time Monitoring of Drug Release.
Ebaston TM; Rozovsky A; Zaporozhets A; Bazylevich A; Tuchinsky H; Marks V; Gellerman G; Patsenker LD
ChemMedChem; 2019 Oct; 14(19):1727-1734. PubMed ID: 31403246
[TBL] [Abstract][Full Text] [Related]
22. Drug delivery and release systems for targeted tumor therapy.
Böhme D; Beck-Sickinger AG
J Pept Sci; 2015 Mar; 21(3):186-200. PubMed ID: 25703117
[TBL] [Abstract][Full Text] [Related]
23. Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells.
Lim SH; Jeong YI; Moon KS; Ryu HH; Jin YH; Jin SG; Jung TY; Kim IY; Kang SS; Jung S
Int J Pharm; 2010 Mar; 387(1-2):209-14. PubMed ID: 19945519
[TBL] [Abstract][Full Text] [Related]
24. Disulfide cross-linked polyurethane micelles as a reduction-triggered drug delivery system for cancer therapy.
Yu S; Ding J; He C; Cao Y; Xu W; Chen X
Adv Healthc Mater; 2014 May; 3(5):752-60. PubMed ID: 24574261
[TBL] [Abstract][Full Text] [Related]
25. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
26. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.
Zou A; Chen Y; Huo M; Wang J; Zhang Y; Zhou J; Zhang Q
J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894
[TBL] [Abstract][Full Text] [Related]
27. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.
Dai W; Jin W; Zhang J; Wang X; Wang J; Zhang X; Wan Y; Zhang Q
Pharm Res; 2012 Oct; 29(10):2902-11. PubMed ID: 22723122
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
[TBL] [Abstract][Full Text] [Related]
29. Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery.
Joo JY; Park GY; An SS
Int J Nanomedicine; 2015; 10 Spec Iss(Spec Iss):101-11. PubMed ID: 26366073
[TBL] [Abstract][Full Text] [Related]
30. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
31. Enzyme-Triggered Morphological Transition of Peptide Nanostructures for Tumor-Targeted Drug Delivery and Enhanced Cancer Therapy.
Cao M; Lu S; Wang N; Xu H; Cox H; Li R; Waigh T; Han Y; Wang Y; Lu JR
ACS Appl Mater Interfaces; 2019 May; 11(18):16357-16366. PubMed ID: 30991000
[TBL] [Abstract][Full Text] [Related]
32. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
Liu CW; Lin WJ
J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
[TBL] [Abstract][Full Text] [Related]
33. Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro.
Mizusako H; Tagami T; Hattori K; Ozeki T
J Pharm Sci; 2015 Sep; 104(9):2934-40. PubMed ID: 25940848
[TBL] [Abstract][Full Text] [Related]
34. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
35. Oligonucleotides--assembled Au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of Doxorubicin and Cisplatin prodrug.
Shanmugam V; Chien YH; Cheng YS; Liu TY; Huang CC; Su CH; Chen YS; Kumar U; Hsu HF; Yeh CS
ACS Appl Mater Interfaces; 2014 Mar; 6(6):4382-93. PubMed ID: 24559392
[TBL] [Abstract][Full Text] [Related]
36. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
37. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
38. Superparamagnetic Reduction/pH/Temperature Multistimuli-Responsive Nanoparticles for Targeted and Controlled Antitumor Drug Delivery.
Zeng J; Du P; Liu L; Li J; Tian K; Jia X; Zhao X; Liu P
Mol Pharm; 2015 Dec; 12(12):4188-99. PubMed ID: 26554495
[TBL] [Abstract][Full Text] [Related]
39. Nanospheres of doxorubicin as cross-linkers for a supramolecular hydrogelation.
Xue Q; Ren H; Xu C; Wang G; Ren C; Hao J; Ding D
Sci Rep; 2015 Mar; 5():8764. PubMed ID: 25739554
[TBL] [Abstract][Full Text] [Related]
40. Tumor-activated prodrug (TAP)-conjugated nanoparticles with cleavable domains for safe doxorubicin delivery.
Guarnieri D; Biondi M; Yu H; Belli V; Falanga AP; Cantisani M; Galdiero S; Netti PA
Biotechnol Bioeng; 2015 Mar; 112(3):601-11. PubMed ID: 25220931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
